Cargando…

Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor

During malignant transformation, a growing body of mutations accumulate in cancer cells which not only drive cancer progression but also endow cancer cells with high immunogenicity. However, because one or multiple steps in cancer-immunity cycle are impaired, anti-cancer immune response is too weak...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Xianguang, Yi, Ming, Jiao, Ying, Chu, Qian, Wu, Kongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857659/ https://www.ncbi.nlm.nih.gov/pubmed/31807028 http://dx.doi.org/10.2147/OTT.S224013

Ejemplares similares

Gut microbiome modulates efficacy of immune checkpoint inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma
por: Yi, Ming, et al.
Publicado: (2021)

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
por: Yi, Ming, et al.
Publicado: (2019)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

Prospects for combining immune checkpoint blockade with PARP inhibition
por: Li, Anping, et al.
Publicado: (2019)

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
por: Ravi, Rajani, et al.
Publicado: (2018)

S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas
por: Mehdi, A., et al.
Publicado: (2023)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
por: Niu, Mengke, et al.
Publicado: (2023)

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
por: Yi, Ming, et al.
Publicado: (2022)

ENPEP as a potential predictor of immune checkpoint inhibitor efficacy
por: Wang, Aoyun, et al.
Publicado: (2021)

Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
por: Sow, Heng Sheng, et al.
Publicado: (2019)

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
por: Yi, Ming, et al.
Publicado: (2021)

TGF-β receptor inhibitor LY2109761 enhances the radiosensitivity of gastric cancer by inactivating the TGF-β/SMAD4 signaling pathway
por: Yang, Tian, et al.
Publicado: (2019)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

The efficacy of immune checkpoint inhibitors in thoracic malignancies
por: Remon, Jordi, et al.
Publicado: (2021)

FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy
por: Ring, Jennifer, et al.
Publicado: (2015)

Inhibition of Wilms' Tumor Proliferation and Invasion by Blocking TGF-β Receptor I in the TGF-β/Smad Signaling Pathway
por: Shi, Qinlin, et al.
Publicado: (2020)

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors
por: Zhang, Lin, et al.
Publicado: (2022)

Transforming of the Tumor Microenvironment: Implications for TGF-β Inhibition in the Context of Immune-Checkpoint Therapy
por: Löffek, Stefanie
Publicado: (2018)

The role of TGF-β/SMAD4 signaling in cancer
por: Zhao, Ming, et al.
Publicado: (2018)

Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks
por: Fanciulli, Giuseppe, et al.
Publicado: (2020)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy
por: Wu, Qinghua, et al.
Publicado: (2022)

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
por: Tang, Hui, et al.
Publicado: (2021)

The TGFβ type I receptor TGFβRI functions as an inhibitor of BMP signaling in cartilage
por: Wang, Weiguang, et al.
Publicado: (2019)

OTUD4 enhances TGFβ signalling through regulation of the TGFβ receptor complex
por: Jaynes, Patrick William, et al.
Publicado: (2020)

The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017
por: Bai, Xianguang, et al.
Publicado: (2020)

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
por: Holmgaard, Rikke B., et al.
Publicado: (2018)

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
por: Wu, Kongju, et al.
Publicado: (2019)

Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer
por: Kang, Yong-Bo, et al.
Publicado: (2021)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

Influence of Microbiome and Antibiotics on the Efficacy of Immune Checkpoint Inhibitors
por: Patel, Priyanka, et al.
Publicado: (2021)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial
por: Metropulos, Anastasia E., et al.
Publicado: (2022)

CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-β Signaling
por: Kim, Bo-Reum, et al.
Publicado: (2020)

Two Cases of Immune Checkpoint Inhibitor-Induced Myocarditis With Complete Atrioventricular Block
por: Kondo, Hisaya, et al.
Publicado: (2023)

Immune checkpoint inhibitor myocarditis with complete heart block: a case series
por: O'shea, M, et al.
Publicado: (2023)

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
por: González-Navajas, Jose M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o4isbo3otbj6a8esrbfc9le4ua